Status | Study |
Completed |
Study Name: Open Label, Phase III Study of NABI-IGIV 10% [Immune Globulin Intravenous(Human), 10%] In Subjects With Primary Immune Deficiency Disorders (PIDD) Condition: Primary Immune Deficiency Disorders (PIDD) Date: 2007-10-01 Interventions: Biological: Nabi-IGIV 10% [Immune Globulin Intravenous (Human). 10%] Nabi-IGIV 10% [Immune Globulin Intr |
Completed |
Study Name: A Clinical Study of Intravenous Immunoglobulin Condition: Immunologic Deficiency Syndromes Date: 2007-05-01 Interventions: Drug: Immune Globulin Intravenous (Human) Omr-IgG-am IGIV IGIV infusions of 300-900 mg/kg every 3 or 4 w |
Completed |
Study Name: Efficacy, Safety and Pharmacokinetics of Gammaplex in Primary Immunodeficiency Diseases. Condition: Primary Immunodeficiency Common Variable Hypogammaglobulinemia Date: 2006-01-18 Interventions: Biological: Gammaplex (Intravenous immunoglobulin) GAMMAPLEX 5g/100 mL, dose is 300-800 mg/kg/infusion e |